Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The first page asked for basic details: name, email, age and location
(PubMed) Imbe A, Tanimoto K, Inaba Y, et al
Try something new
Loss of appetite to discomfort: Some users may feel too full , reducing food intake more than intended
Make-up should harmonize with your outfit, hairstyle and accessories
India, 2022) 3,170 (3 mg), 3,520 (7 mg), 3,870 (14 mg) MOUNJARO (Tirzepatide GLP & GIP agonist) Eli Lilly Weekly injection (starting 2.5 mg) Dual agonist breakthrough Not yet approved ZEBOUND (Tirzepatide) Eli Lilly Weekly injection (starting 2.5 mg) Approved for weight loss (US, 2023) ~$1,060/4 injections (88,000) Not available VICTOZA (Liraglutide GLP-1) Novo Nordisk Daily injection: 0.6 mg For Type 2 diabetes (India, 2010) 5,324/month APLEVANT (Dulaglutide GLP-1) Eli Lilly (sold by Lupin in India) Weekly injection: 0.75 mg For Type 2 diabetes (India, 2018) 5,497 per pre-filled pen BYETTA (Exenatide GLP-1) Eli Lilly Twice-daily injection: 0.005 mg Approved for Type 2 diabetes (2007) 6,957 for 60-dose pen Pipeline & Research Therapies GLOO34 (Sun Pharma GLP-1 agonist) Under development in India for obese & overweight patients without diabetes
